Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 10, 2014, Pages 879-885

  Zhou, Hongyan ^a   Jiang, Sheng ^b   Chen, Jianping ^a   Su, Shao Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

Angiogenesis; CNV; HDACs; SAHA

Indexed keywords

ADAMTS1 PROTEIN; EPIDERMAL GROWTH FACTOR; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VORINOSTAT; ADAM PROTEIN; ADAMTS1 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; HISTONE DEACETYLASE; HYDROXAMIC ACID; SPZ1 PROTEIN, HUMAN; THROMBOSPONDIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COMPLICATION; CORNEA; DRUG EFFECTS; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ADAM PROTEINS; ADMINISTRATION, OPHTHALMIC; ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL MOVEMENT; CELL PROLIFERATION; CORNEA; EPIDERMAL GROWTH FACTOR; FEMALE; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INFLAMMATION; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSPONDINS; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84907556201     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0117     Document Type: Article

References (46)

1. Armeanu, S., Pathil, A., Venturelli, S., Mascagni, P., Weiss, T.S., Gottlicher, M., et al. 2005. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J. Hepatol. 42(2): 210- 217. doi:10.1016/j.jhep.2004.10.020. PMID:15664246.
2. Bagui, T.K., Sharma, S.S., Ma, L., and Pledger, W.J. 2013. Proliferative status regulates HDAC11 mRNA abundance in nontransformed fibroblasts. Cell Cycle, 12(21): 3433-3441. doi:10.4161/cc.26433. PMID:24047695.
3. Barr, J. 2004. Jan. Contact Lens Spectrum 2005. Annual Report.
4. Biswas, P.S., and Rouse, B.T. 2005. Early events in HSV keratitis-setting the stage for a blinding disease. Microbes Infect. 7(4): 799-810. doi:10.1016/j.micinf. 2005.03.003. PMID:15857807.
5. Chen, B., and Cepko, C.L. 2009. HDAC4 regulates neuronal survival in normal and diseased retinas. Science, 323(5911): 256-259. doi:10.1126/science.1166226. PMID:19131628.
6. Choo, Q.Y., Ho, P.C., Tanaka, Y., and Lin, H.S. 2010. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharidestimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford), 49(8): 1447- 1460. doi:10.1093/rheumatology/keq108. PMID:20421217.
7. Chou, C.W., and Chen, C.C. 2008. HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett. 582(29): 4059-4065. doi:10.1016/j.febslet. 2008.10.048. PMID:19007777.
8. Codd, R., Braich, N., Liu, J., Soe, C.Z., and Pakchung, A.A. 2009. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Int. J. Biochem. Cell Biol. 41(4): 736-739. doi:10.1016/j.biocel.2008.05. 026. PMID:18725319.
9. Den, S., Sotozono, C., Kinoshita, S., and Ikeda, T. 2004. Efficacy of early systemic betamethasone or cyclosporin A after corneal alkali injury via inflammatory cytokine reduction. Acta Ophthalmol. Scand. 82(2): 195-199. doi:10.1111/j. 1600-0420.2004.00229.x. PMID:15043540.
10. Deroanne, C.F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., et al. 2002. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21(3): 427-436. doi:10. 1038/sj.onc.1205108. PMID:11821955.
11. Epstein, R.J., Stulting, R.D., Hendricks, R.L., and Harris, D.M. 1987. Corneal neovascularization. Pathogenesis and inhibition. Cornea, 6(4): 250-257. doi:10. 1097/00003226-198706040-00004. PMID:2446823.
12. Fandy, T.E., Shankar, S., Ross, D.D., Sausville, E., and Srivastava, R.K. 2005. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7(7): 646-657. doi:10.1593/neo. 04655. PMID:16026644.
13. Glesne, D.A., Zhang, W., Mandava, S., Ursos, L., Buell, M.E., Makowski, L., and Rodi, D.J. 2006. Subtractive transcriptomics: establishing polarity drives in vitro human endothelial morphogenesis. Cancer Res. 66(8): 4030-4040. doi: 10.1158/0008-5472.CAN-05-3294. PMID:16618722.
14. Glozak, M.A., and Seto, E. 2007. Histone deacetylases and cancer. Oncogene, 26(37): 5420-5432. doi:10.1038/sj.onc.1210610. PMID:17694083.
15. Ha, C.H., Wang, W., Jhun, B.S., Wong, C., Hausser, A., Pfizenmaier, K., et al. 2008. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J. Biol. Chem. 283(21): 14590-14599. doi:10.1074/ jbc.M800264200. PMID:18332134.
16. Han, E.S., Wee, W.R., Lee, J.H., and Kim, M.K. 2011. Long-term outcome and prognostic factor analysis for keratolimbal allografts. Graefes Arch. Clin. Exp. Ophthalmol. 249(11): 1697-1704. doi:10.1007/s00417-011-1760-3. PMID:21837442.
17. Jeong, J.W., Bae, M.K., Ahn, M.Y., Kim, S.H., Sohn, T.K., Bae, M.H., et al. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell, 111(5): 709-720. doi:10.1016/S0092-8674(02)01085-1. PMID:12464182.
18. Kenyon, B.M., Voest, E.E., Chen, C.C., Flynn, E., Folkman, J., and D'Amato, R.J. 1996. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37(8): 1625-1632. PMID:8675406.
19. Lane, A.A., and Chabner, B.A. 2009. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32): 5459-5468. doi:10.1200/JCO.2009.22.1291. PMID: 19826124.
20. Lee, P., Wang, C.C., and Adamis, A.P. 1998. Ocular neovascularization: an epidemiologic review. Surv. Ophthalmol. 43(3): 245-269. doi:10.1016/S0039-6257 (98)00035-6. PMID:9862312.
21. Li, N., Wang, X., Wan, P., Huang, M., Wu, Z., Liang, X., et al. 2011. Tectonic lamellar keratoplasty with acellular corneal stroma in high-risk corneal transplantation. Mol. Vis. 17: 1909-1917. PMID:21850165.
22. Liang, C.C., Park, A.Y., and Guan, J.L. 2007. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2(2): 329-333. doi:10.1038/nprot.2007.30. PMID:17406593.
23. Lin, C.M., Chang, H., Chen, Y.H., Li, S.Y., Wu, I.H., and Chiu, J.H. 2006. Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int. Immunopharmacol. 6: 1690-1698. doi:10.1016/j.intimp.2006. 07.003. PMID:16979123.
24. Lu, P., Li, L., Liu, G., Baba, T., Ishida, Y., Nosaka, M., et al. 2012. Critical role of TNF-alpha-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization. Invest. Ophthalmol. Vis. Sci. 53(7): 3516- 3526. doi:10.1167/iovs.10-5548. PMID:22570350.
25. Marks, P.A. 2007. Discovery and development of SAHA as an anticancer agent. Oncogene, 26(9): 1351-1356. doi:10.1038/sj.onc.1210204. PMID:17322921.
26. Marks, P.A., and Xu, W.S. 2009. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem. 107(4): 600-608. doi:10.1002/jcb.22185. PMID:19459166.
27. Marks, P.A., Richon, V.M., and Rifkind, R.A. 2000. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92(15): 1210-1216. doi:10.1093/jnci/92.15.1210. PMID:10922406.
28. Pandya, N.M., Dhalla, N.S., and Santani, D.D. 2006. Angiogenesis-a new target for future therapy. Vascul. Pharmacol. 44(5): 265-274. doi:10.1016/j.vph.2006. 01.005. PMID:16545987.
29. Phillips, G.D., Stone, A.M., Jones, B.D., Schultz, J.C., Whitehead, R.A., and Knighton, D.R. 1994. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo, 8(6): 961-965. PMID: 7539637.
30. Polverini, P.J. 1995. The pathophysiology of angiogenesis. Crit. Rev. Oral Biol. Med. 6(3): 230-247. doi:10.1177/10454411950060030501. PMID:8785263.
31. Qian, D.Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H.M., Salumbides, B., et al. 2006. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2): 634-642. doi:10. 1158/1078-0432.CCR-05-1132. PMID:16428510.
32. Reinhard, T., and Larkin, F. (Editors). 2006. Cornea and external eye disease. Springer, Germany.
33. Richon, V.M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R.A., and Marks, P.A. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 95(6): 3003-3007. doi:10.1073/pnas.95.6.3003. PMID:9501205.
34. Richon, V.M., Sandhoff, T.W., Rifkind, R.A., and Marks, P.A. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97(18): 10014-10019. doi:10. 1073/pnas.180316197. PMID:10954755.
35. Richon, V.M., Zhou, X., Rifkind, R.A., and Marks, P.A. 2001. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood. Cells Mol. Dis. 27(1): 260-264. doi:10.1006/bcmd. 2000.0376. PMID:11358386.
36. Sachdev, U., Cui, X., Hong, G., Namkoong, S., Karlsson, J.M., Baty, C.J., and Tzeng, E. 2012. High mobility group box 1 promotes endothelial cell angiogenic behavior in vitro and improves muscle perfusion in vivo in response to ischemic injury. J. Vasc. Surg. 55(1): 180-191. doi:10.1016/j.jvs.2011.07.072. PMID:21944908.
37. Scorcia, V., and Busin, M. 2012. Survival of mushroom keratoplasty performed in corneas with postinfectious vascularized scars. Am. J. Ophthalmol. 153(1): 44-50.e41. doi:10.1016/j.ajo.2011.05.020. PMID:21851921.
38. Sennlaub, F., Courtois, Y., and Goureau, O. 1999. Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization. Invest. Ophthalmol. Vis. Sci. 40(12): 2773-2779. PMID:10549635.
39. Stevenson, W., Cheng, S.F., Dastjerdi, M.H., Ferrari, G., and Dana, R. 2012. Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul. Surf. 10(2): 67-83. doi:10. 1016/j.jtos.2012.01.005. PMID:22482468.
40. Ugur, H.C., Ramakrishna, N., Bello, L., Menon, L.G., Kim, S.K., Black, P.M., and Carroll, R.S. 2007. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J. Neurooncol. 83(3): 267-275. doi:10.1007/s11060-007-9337-z. PMID: 17310267.
41. van der Meer, A.D., Vermeul, K., Poot, A.A., Feijen, J., and Vermes, I. 2010. A microfluidic wound-healing assay for quantifying endothelial cell migration. Am. J. Physiol. Heart Circ. Physiol. 298(2): H719-H725. doi:10.1152/ajpheart. 00933.2009. PMID:19933413.
42. Wang, S., Li, X., Parra, M., Verdin, E., Bassel-Duby, R., and Olson, E.N. 2008. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc. Natl. Acad. Sci. U.S.A. 105(22): 7738-7743. doi:10. 1073/pnas.0802857105. PMID:18509061.
43. Wierman, M.B., and Smith, J.S. 2013. Yeast sirtuins and the regulation of aging. FEMS Yeast Res. 14(1): 73-88. doi:10.1111/1567-1364.12115. PMID:24164855.
44. Xiao, O., Xie, Z.L., Lin, B.W., Yin, X.F., Pi, R.B., and Zhou, S.Y. 2012. Minocycline inhibits alkali burn-induced corneal neovascularization in mice. PLoS One, 7(7): e41858. doi:10.1371/journal.pone.0041858. PMID:22848638.
45. Xu, W.S., Parmigiani, R.B., and Marks, P.A. 2007. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene, 26(37): 5541-5552. doi:10.1038/ sj.onc.1210620. PMID:17694093.
46. Zhou, B., Ma, R., Si, W., Li, S., Xu, Y., Tu, X., and Wang, Q. 2013. MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett. 333(2): 159-169. doi:10.1016/j.canlet.2013.01.028. PMID:23352645.